Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS)

Caselli, Chiara; Di Giorgi, Nicoletta; Ragusa, Rosetta; Lorenzoni, Valentina; Smit, Jeff; El Mahdiui, Mohammed; Buechel, Ronny R; Teresinska, Anna; Pizzi, Maria N; Roque, Albert; Poddighe, Rosa; Knuuti, Juhani; Schütte, Moritz; Parodi, Oberdan; Pelosi, Gualtiero; Scholte, Arthur; Rocchiccioli, Silvia; Neglia, Danilo

doi:10.1016/j.vph.2022.107098

Citations

Citation copied

Caselli, C., Di Giorgi, N., Ragusa, R., Lorenzoni, V., Smit, J., El Mahdiui, M., Buechel, R. R., Teresinska, A., Pizzi, M. N., Roque, A., Poddighe, R., Knuuti, J., Schütte, M., Parodi, O., Pelosi, G., Scholte, A., Rocchiccioli, S., & Neglia, D. (2022). Association of MMP9 with adverse features of plaque progression and residual inflammatory risk in patients with chronic coronary syndrome (CCS). Vascular Pharmacology, 146, 107098. https://doi.org/10.1016/j.vph.2022.107098

Abstract

BACKGROUND AND AIMS

MMP-9 is a predictor of atherosclerotic plaque instability and adverse cardiovascular events, but longitudinal data on the association between MMP9 and coronary disease progression are lacking. This study is aimed at investigating whether MMP9 is associated with atherosclerotic plaque progression and the related molecular basis in stable patients with chronic coronary syndrome (CCS).

METHODS

MMP9 serum levels were measured in 157 CCS patients (58 ± 8 years of age; 66% male) undergoing coronary computed tomograph